Advokatfirman Lindahl represented the sellers of Abboxia in the strategic merger with FrostPharma. The two companies are now merging under the name of FrostPharma and will thus become one of the leading specialist pharmaceutical companies with the widest range of hospital drugs in the Nordic Region.
The merger combines FrostPharma’s commercial strength and strategic alliances with Abboxia’s development capacity, thus allowing more extensive supply of hospital medicines to Nordic healthcare providers.
The Lindahl team consisted of Svante Liljedahl, Olivia Sandin and Jannica Stefansson.
About FrostPharma and Abboxia
FrostPharma, which was founded in 2016, focuses on strategic partnerships and commercialisation of specialist pharmaceuticals in the Nordic market. Abboxia, which was founded in 2017, has developed several specialist medicines for the hospital segment in the Nordic Region.
Read more in the FrostPharma press release here.
